Preventive Effect of Shenduning Prescription Combined with Hydration Therapy on Contrast Induced Nephronpathy after Elective Percutaneous Coronary Intervention
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v2i2.369
Abstract
Objective — To explore the preventive effect of Shenduning prescription combined with hydration therapy on contrast induced nephronpathy (CIN) after elective percutaneous coronary intervention. Methods — 159 patients undergoing selective coronary intervention were divided into simple hydration group, intensive statin group and Shenduning prescription group randomly, with 53 cases in each group. The simple hydration group received conventional drugs for coronary heart disease and preoperative routine hydration therapy. The intensive statin group received intensive treatment with atorvastatin calcium tablets on the basis of the simple hydration group, and the Shenduning prescription group received Shenduning prescription treatment on the basis of the hydration group. Serum creatinine (Scr), malondialdehyde (MDA), superoxide dismutase (SOD) and glomerular filtration rate (eGFR) were detected by blood samples at 24h before and after operation, as well as 72h after operation respectively. The primary endpoint event was the occurrence of CI-AKI. Results — The Scr level of the intensive statin group and the Shenduning prescription group was significantly lower than that of the simple hydration group, while the eGFR level was significantly higher than that of the simple hydration group, which is of statistical significance (P<0.05). The incidence of CI-AKI was 15.1% in simple hydration group, 5.7% in intensive statin group and 3.8% in Shenduning prescription group respectively after operation (χ2 = 5.194, P=0.075), of which there was significant statistical difference between simple hydration group and Shenduning prescription group (χ2 = 3.975, P=0.046). After 72h of the operation, MDA level in Shenduning prescription group was significantly lower than that in simple hydration group and intensive statin group, while its SOD level was significantly higher than that in simple hydration group and intensive statin group, which is of statistical significance (P<0.05). The proportion of abnormal liver function in intensive statin group and the Shenduning prescription group was 13.1% and 3.8%, respectively, and the difference was statistically significant (χ2 = 4.867, P=0.027). Conclusion — The combination treatment of Shenduning prescription with hydration therapy may protect the patient’s renal function after elective coronary interventional therapy, while reducing the incidence of CIN and the oxidative stress reaction caused by contrast agent, thus effectively reducing adverse reactions.
Keywords
percutaneous coronary intervention, hydration therapy, Shenduning prescription, contrast induced nephronpathy, glomerular filtration rate
Full Text
PDF - Viewed/Downloaded: 21 TimesIndexation
Download Index RecordReferences
[2]Prit Kusirisin, Siriporn C. Chattipakorn, Nipon Chattipakorn, et al. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches[J]. J Transl Med. 2020; 18: 400. doi: 10.1186/s12967-020-02574-8.
[3]Ashkan Heshmatzadeh Behzadi, Behzad Amoozgar, Shalini Jain, et al. Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty[J]. Medicine (Baltimore). 2021; 100(10): e24603. doi: 10.1097/MD.0000000000024603.
[4]Jiantong Hou, Gaoliang Yan, Bo Liu, et al. The Protective Effects of Enalapril Maleate and Folic Acid Tablets against Contrast-Induced Nephropathy in Diabetic Rats[J]. Biomed Res Int. 2018; 2018: 4609750. doi: 10.1155/2018/4609750.
[5]Yanfei Li, Ke Ren. The Mechanism of Contrast-Induced Acute Kidney Injury and Its Association with Diabetes Mellitus[J]. Contrast Media Mol Imaging. 2020; 2020: 3295176. doi: 10.1155/2020/3295176.
[6]Hui-Chao Pan, Xian-Hao Wu, Qian-Li Wan, et al. Analysis of the risk factors for contrast-induced nephropathy in over-aged patients receiving coronary intervention[J]. Exp Biol Med (Maywood). 2018; 243(12): 970–975. doi: 10.1177/1535370218799973.
[7]Li Lei, Yibo He, Zhaodong Guo, et al. A Simple Nomogram to Predict Contrast-Induced Acute Kidney Injury in Patients with Congestive Heart Failure Undergoing Coronary Angiography[J]. Cardiol Res Pract. 2021; 2021: 9614953. doi: 10.1155/2021/9614953.
[8]Min Liang, Shicheng Yang, Naikuan Fu. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy[J]. Medicine (Baltimore). 2017; 96(27): e7384. doi: 10.1097/MD.0000000000007384.
[9]Arezoo Khosravi, Mitra Dolatkhah, Hesam Sadat Hashemi, et al. Preventive Effect of Atorvastatin (80 mg) on Contrast-Induced Nephropathy After Angiography in High-Risk Patients: Double-Blind Randomized Clinical Trial[J]. Nephrourol Mon. 2016; 8(3): e29574. doi: 10.5812/numonthly.29574.
[10]Hamid Sanei, Alireza Hajian-Nejad, Amirreza Sajjadieh-Kajouei, et al. Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients undergoing computed tomography angiography[J]. ARYA Atheroscler. 2014; 10(5): 252–258.
[11]Wei-Jie Bei, Shi-Qun Chen, Hua-Long Li, et al. Comparing common doses (double-dose vs usual-dose) of atorvastatin for preventing contrast-induced acute kidney injury and mortality after coronary angiography[J]. Medicine (Baltimore). 2017; 96(30): e7501. doi: 10.1097/MD.0000000000007501.
[12]Laura Vicente-Vicente, David González-Calle, Alfredo Ginés Casanova, et al. Quercetin, a Promising Clinical Candidate for The Prevention of Contrast-Induced Nephropathy[J]. Int J Mol Sci. 2019; 20(19): 4961. doi: 10.3390/ijms20194961.
[13]Dongling Liu, Feng Gao, Li Li, et al. The prophylactic effect of alprostadil on contrast-induced nephropathy in renal insufficiency patients after percutaneous coronary intervention[J]. Am J Transl Res. 2021; 13(4): 3766–3772.
[14]Yi-Hsin Chen, Yun-Ching Fu, Ming-Ju Wu. Does Resveratrol Play a Role in Decreasing the Inflammation Associated with Contrast Induced Nephropathy in Rat Model?[J]. J Clin Med. 2019; 8(2): 147. doi: 10.3390/jcm8020147.
[15]Cailan Li, Qian Li, Jiamin Xu, et al. The Efficacy and Safety of Compound Danshen Dripping Pill Combined with Percutaneous Coronary Intervention for Coronary Heart Disease[J]. Evid Based Complement Alternat Med. 2020; 2020: 5067137. doi: 10.1155/2020/5067137.
[16]Jingjing Zhao, Huahua Liu, Buyun Xu, et al. The Role of Xuefu Zhuyu Decoction in Prevention of Contrast-Induced Nephropathy after Percutaneous Coronary Intervention[J]. Evid Based Complement Alternat Med. 2020; 2020: 5419016. doi: 10.1155/2020/5419016.
[17]QIAN Lu, FU Xiaojun, HE Liqun. Effects of Shendu Ning Agent on the release of Vasoactive Substances in Patients with Chronic Kidney Disease[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine. 2011; 21(4): 219-224.
[18] Xiong Rongbing, Zhang Ting, He Liqun, et al. Experimental Study on the Protective Effect of Shenduning Granule on Renal Failure Model Rats and its Mechanism[J]. Journal of Emergency in Traditional Chinese Medicine. 2017; 26(5): 775-778. doi:10.3969/j.issn.1004-745X.2017.05.007.
[19] Xiong Rongbing, He Liqun, FU Xiaojun. Experimental Study on the Effects of Shenduning Particles on Antioxidant and MCP-1 Inflammatory Factors in Renal Tissues of Chronic Renal Failure[J]. Chinese Journal of Integrated Traditional and Western Nephrology. 2018; 19(4): 288-291.
Copyright © 2021 Jiangang Jiang, Xianqing Hu, Ningning Ji, Chengyuan Yan, Jingliang Lan, Xiaoma Du
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License